FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment

FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment
The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. A decision is expected by April 6, 2018. Clovis submitted the application, which specifies that the maintenance treatment should be used in women who are sensitive to

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *